Medimetriks Pharmaceuticals

What Medimetriks Pharmaceuticals does

Medimetriks Pharmaceuticals, Inc. is a privately held specialty pharmaceutical company founded in 2007 and headquartered in Parsippany, New Jersey, focused exclusively on the U.S. Dermatology and Podiatry markets. The company develops, in-licenses, and commercializes a portfolio of ten prescription skincare brands addressing conditions including acne vulgaris, rosacea, atopic dermatitis, seborrheic dermatitis, fungal infections, dystrophic nails, and impetigo. Notable products include Clindacin P and ETZ (topical clindamycin pledgets), Genadur (the first FDA-approved hydrosoluble nail lacquer for fragile, brittle nails), Ketodan Foam, Neuac combination gel, Sumadan Wash (which incorporates Novasome time-release delivery technology), Synalar cream and ointment, Tovet Foam, and Neo-Synalar combination cream. The company historically pursued novel pipeline assets via licensing, including ozenoxacin from Ferrer Internacional (2014) and OPA-15406, a topical PDE-4 inhibitor for atopic dermatitis, from Otsuka Pharmaceutical in 2016 for $22 million upfront.

Medimetriks generates revenue primarily through prescription pharmaceutical sales, supported by a national sales force promoting its brands directly to dermatologists and podiatrists, with patient access facilitated through instant rebate card programs. The company also operates a business development function that commercializes and out-licenses assets on behalf of biotech, generic, and development partners, creating a secondary revenue stream from milestone payments and commercialization rights. The company employs 101-250 people and, according to a 2010 IMS Health reference, had reached over 1 million annual prescriptions for its clindamycin product category. Leadership includes COO David Addis and CFO R. Brent Lenczycki, both with prior specialty pharma experience at Bradley Pharmaceuticals.

In a significant recent development, Medimetriks' U.S. rights to Xepi (ozenoxacin) cream appear to have transferred to Pelthos Therapeutics by 2025, indicating portfolio contraction. The company remains operating as of 2025-2026, with a publicly available 2025 Corporate Overview PDF and active website, but no recent product launches, funding rounds, or strategic transactions are disclosed beyond the 2016 licensing activity.

Name

Medimetriks Pharmaceuticals

Legal name

Medimetriks Pharmaceuticals, Inc.

Website

https://medimetriks.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

101–250 employees

Short description

Medimetriks Pharmaceuticals is a privately held specialty pharmaceutical company that develops, in-licenses, and commercializes prescription skincare brands for the U.S. Dermatology and Podiatry markets through a national sales force targeting dermatologists and podiatrists.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals - Dermatology and Podiatry

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)

akta.pro secondary industries

Dermatology Specialty Pharmaceuticals (HLAIACAL), Topical & Dermatology Generics (HLAIABAE), Psoriasis & Eczema Specialty Care (HLAKACAL)

Keywords

• Specialty pharmaceutical products
• Prescription dermatology treatments
• Topical skincare medications
• Podiatry pharmaceutical brands
• Prescription drug commercialization

Headquarters

HQ city

New Jersey

HQ country

Trinidad & Tobago

HQ region

Latin America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Marketing or Sales, Personnel, Supply Chain, Technology or R&D, Operations

Revenue model

1. Prescription Pharmaceutical Sales: Medimetriks generates revenue through the commercialization of prescription skincare brands including topical antibiotics, antifungals, corticosteroids, and combination therapies for dermatology and podiatry conditions. Products are sold through prescription with patient rebate programs.
2. Licensing and Commercialization Services: The company provides commercialization expertise to biotech, generic, and development companies, including creating brands, maximizing life cycles, and generating value through licensing agreements. Revenue comes from milestone payments and commercialization rights.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels1 record

Core offering

Medimetriks Pharmaceuticals is a privately held U.S. specialty pharmaceutical company that develops, licenses, and commercializes a portfolio of prescription skincare brands marketed exclusively to the dermatology and podiatry specialties. Its ten branded products treat acne, rosacea, atopic dermatitis, seborrheic dermatitis, fungal infections, dystrophic nails, and impetigo, and are promoted through a national sales force that calls on dermatologists and podiatrists and supported by patient rebate programs. The company additionally offers commercialization expertise and licensing services to biotech, generic, and development partners.

Product overview

Medimetriks Pharmaceuticals is a specialty pharmaceutical company focused on the Dermatology and Podiatry markets. The company commercializes a portfolio of innovative prescription skincare brands treating conditions including acne, rosacea, atopic dermatitis, fungal infections, dystrophic nails, and impetigo. The product portfolio consists of ten distinct prescription brands including topical antibiotics (Clindacin P, Clindacin ETZ, Neuac), antifungal treatments (Ketodan Foam), steroid formulations (Synalar Cream, Synalar Ointment, Tovet Foam, Neo-Synalar Cream), a nail lacquer treatment (Genadur), and a cleanser for acne and rosacea (Sumadan Wash). Products are promoted through a national sales force and supported by patient savings programs including instant rebate cards.

Differentiator

Problem solved

Functional benefit

Products and services

• Clindacin P (clindamycin phosphate topical solution USP, 1% pledget) Topical clindamycin phosphate pledget indicated for the treatment of acne vulgaris, applied via convenient pad applicator to shoulders, chest, back, and face.
• Clindacin ETZ (clindamycin phosphate topical solution USP, 1% pledget) Individually wrapped topical clindamycin phosphate pledgets for the treatment of acne vulgaris, with 60 pledgets per pack for convenient application on multiple body areas.
• Genadur (hydrosoluble nail lacquer) Hydrosoluble nail lacquer indicated to protect intact or damaged nails from moisture, friction, and shear effects, and recognized as the first FDA-approved brand for the treatment of fragile, brittle nails.
• Ketodan Foam (ketoconazole foam, 2%) Topical ketoconazole foam indicated for seborrheic dermatitis in immunocompetent patients aged 12 and older, suitable for hair-bearing areas on scalp, face, and body.
• Neo-Synalar Cream (neomycin sulfate 0.5%, fluocinolone acetonide 0.025%) Combination cream of a steroid and antibiotic for the treatment of corticosteroid-responsive dermatoses with secondary infection, including atopic dermatitis complicated by bacterial infection.
• Neuac Gel (clindamycin phosphate and benzoyl peroxide, 1.2%/5%) Fixed-dose combination topical gel of clindamycin phosphate and benzoyl peroxide for inflammatory acne vulgaris, with clinical studies demonstrating greater efficacy than either ingredient alone.
• Sumadan Wash (sodium sulfacetamide 9% and sulfur 4.5%) Topical wash for the control of acne vulgaris, acne rosacea, and seborrheic dermatitis, formulated with patented Novasome microstructure delivery technology that delivers emollients over time.
• Synalar Cream (fluocinolone acetonide 0.025%) Class 5 topical corticosteroid cream indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, formulated as a gentle, sulfate-free cream for sensitive skin areas.
• Synalar Ointment (fluocinolone acetonide 0.025%) Preservative-free Class 4 topical corticosteroid ointment in a 100% petrolatum base for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, intended for sensitive atopic dermatitis patients.
• Tovet Foam (clobetasol propionate foam, 0.05%) Super-potent topical steroid emollient foam for inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, including psoriasis and atopic dermatitis, in patients aged 12 and older.

Quantifiable outcome

• 85% reduction in patients reporting lamellar splitting of treated nails with Genadur
• +2 more outcomes

Named customers2 records

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Otsuka Pharmaceutical Co., Ltd.coreStrategic or Co-development Partner · 8 February 2016Licensing agreement granting Medimetriks exclusive development and commercialization rights for OPA-15406 (topical PDE-4 inhibitor) in the U.S. and Puerto Rico. Medimetriks made a $22 million upfront payment and will make milestone payments. Otsuka retained manufacturing rights.
• Ferrer Internacional S.A.coreOEM/ Whitelabel/ Licensing Partner · 1 March 2014Medimetriks licensed exclusive U.S. commercialization rights to ozenoxacin from Ferrer in March 2014. Completed second successful Phase 3 pivotal trial in July 2015 and submitted NDA to FDA in June 2016.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Galderma: Galderma is the largest pure-play dermatology pharmaceutical company globally, offering prescription brands across acne, rosacea, atopic dermatitis, and other skin conditions. Direct comparable to Medimetriks in specialty focus and prescriber channel (dermatologists), though at materially larger scale and with proprietary R&D.
• Almirall: Almirall is a European-headquartered specialty pharmaceutical company with a primary focus on dermatology. Comparable to Medimetriks as an independent, dermatology-focused commercial platform with a portfolio of branded prescription skincare products and an active licensing model.
• Sebela Pharmaceuticals: Sebela Pharmaceuticals is a privately held specialty pharmaceutical company with dermatology and gastroenterology franchises. Comparable to Medimetriks as an independent, private specialty pharma with a dermatology commercial platform built around branded prescription products and selective in-licensing.

Broad incumbents

• Ortho Dermatologics (Bausch Health): Ortho Dermatologics is the dermatology division of Bausch Health, offering a broad prescription dermatology portfolio including acne, actinic keratosis, and aesthetic products. Comparable to Medimetriks in therapeutic categories served (acne, atopic dermatitis) but operates as part of a much larger diversified healthcare conglomerate with greater resources and global reach.
• Sun Pharma (Dermatology Division): Sun Pharmaceutical's dermatology division markets a broad portfolio of branded and generic topical products in the U.S. Comparable to Medimetriks in product categories (acne, rosacea, actinic keratosis with levulan) and dermatology channel focus, but as part of a global generics heavyweight with substantially greater scale.

Emerging players

• Arcutis Biotherapeutics: Arcutis is a late-stage dermatology biopharmaceutical company developing topical treatments for inflammatory skin conditions including atopic dermatitis, psoriasis, and seborrheic dermatitis. Directly comparable to Medimetriks in targeting dermatology with PDE-4 and JAK inhibitor mechanisms for atopic dermatitis, though Arcutis is publicly traded and innovation-driven rather than commercial-led.
• Dermavant Sciences: Dermavant is a clinical-stage dermatology company developing topical therapies for psoriasis, atopic dermatitis, and actinic keratosis. Comparable to Medimetriks in dermatology focus and topical innovation pipeline, with overlapping indication targets (atopic dermatitis, psoriasis) where Medimetriks's OPA-15406 also competes.
• Verrica Pharmaceuticals: Verrica is a dermatology therapeutics company developing topical treatments for skin diseases including molluscum contagiosum and common warts. Comparable to Medimetriks as a focused dermatology commercial-stage company with a small specialty sales force targeting dermatologists.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/medimetriks

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medimetriks Pharmaceuticals